Welcome to our dedicated page for AGTC news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on AGTC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AGTC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AGTC's position in the market.
AGTC has announced the presentation of data from its X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials at the ARVO 2021 Virtual Annual Meeting. The six-month data from the Phase 1/2 XLRP trial indicates a favorable safety profile and improved visual acuity in patients. The company plans to report additional 12-month data from these trials in Q2 2021. AGTC anticipates multiple milestones in the XLRP program throughout 2021 and 2022, continuing its development of gene therapies for rare diseases.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced data presentations from ongoing clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) at the virtual ARVO 2021 Annual Meeting. Paul Yang, MD, will present interim data from the XLRP Phase 1/2 trial, highlighting clinically meaningful improvements in macular sensitivity. Mark Pennesi, MD, will present findings from the ACHM Phase 1/2 studies. The sessions are scheduled for May 3 and May 6, 2021, showcasing AGTC's commitment to developing gene therapies for rare eye diseases.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced the resignation of Mark Shearman, Ph.D., its Chief Scientific Officer, effective June 4, 2021. Dr. Shearman, who played a crucial role in advancing AGTC's gene therapy pipeline, will assist in the transition. AGTC's CEO praised his contributions over the past six years, highlighting the company's progress in clinical programs for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM). The company is actively searching for a new senior research/medical officer to lead further development efforts.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has signed a licensing agreement with SparingVision SAS to provide its proprietary PR1.7 cone specific promoter technology. This technology enhances gene expression in cone photoreceptors for gene therapies targeting inherited retinal disorders. SparingVision will use this in developing two non-competing products, with potential for future projects. AGTC will gain an upfront fee, milestone payments, and royalties from sales.
The collaboration aims to advance treatments for patients with ocular diseases.
AGTC has entered a licensing agreement with TeamedOn to advance gene therapy for X-linked retinoschisis (XLRS), a retinal disease causing vision loss. AGTC will provide clinical trial materials and data for the investigational gene therapy candidate, rAAV2tYF-CB-hRS1. TeamedOn will manage the clinical development, aiming to initiate trials using subretinal injections. AGTC, which had halted its XLRS program in 2018 due to unmet efficacy endpoints, expects to receive milestones and royalties from clinical progress. This collaboration aims to address the urgent treatment needs for XLRS patients.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announces participation in two upcoming virtual conferences. On April 6, 2021, AGTC's management will engage in one-on-one meetings at the Wells Fargo Biotech Corporate Access Day. Additionally, an on-demand corporate update will be available during the Alliance for Regenerative Medicine Cell & Gene Meeting from April 6-9, 2021. AGTC focuses on developing gene therapies for rare diseases and has active clinical trials for conditions like X-linked retinitis pigmentosa.
AGTC announces two initiatives to enhance patient support for its X-linked retinitis pigmentosa (XLRP) clinical trials. A redesigned website will improve accessibility for low vision patients, featuring customizable font sizes and a read-aloud option. Additionally, a dedicated patient information call center, in partnership with Serva Health, will assist potential trial participants with queries and logistics. These efforts underscore AGTC's commitment to incorporating patient feedback and improving trial experiences.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that Jill Dolgin, PharmD, will deliver the keynote address at the virtual Gene Therapy Patient Engagement Summit on March 24, 2021. Dolgin will discuss the importance of a patient-centric approach in advancing gene therapy clinical programs. Emphasizing the significance of patient engagement in the clinical development process, Dolgin aims to translate patient experiences into better outcomes. AGTC is focused on developing genetic therapies for rare diseases, with ongoing trials in conditions like X-linked retinitis pigmentosa and achromatopsia.
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a leading biotechnology firm focused on gene therapies for rare diseases, announced its participation in two significant virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will feature a fireside chat with CEO Sue Washer on March 9, 2021, while the 33rd Annual ROTH Conference will include both Washer and Chief Scientific Officer Mark Shearman on March 15, 2021. Audio webcasts will be available on demand at AGTC's website following each event.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that CEO Sue Washer will participate in the OIS Gene Therapy Innovation Showcase on February 18, 2021, from 12 PM to 3 PM CST. The virtual event will feature a market overview, a start-up spotlight, and a panel discussion focused on gene therapy in eye care. Registration is complimentary. AGTC specializes in AAV-based gene therapies targeting rare ophthalmic and CNS diseases, with ongoing clinical trials in conditions like X-linked retinitis pigmentosa and achromatopsia.
